Search

Displaying results 2611 - 2620 of 10000 in total
  1. Drug

    Tropisetron

    go.drugbank.com/drugs/DB11699
    ApprovedInvestigationalWithdrawn

    Tropisetron is an indole derivative with antiemetic activity. … As a selective serotonin receptor antagonist, tropisetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting

  2. Drug

    Anagrelide

    go.drugbank.com/drugs/DB00261
    ApprovedInvestigational

    [L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g. … Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms.

  3. Drug

    Melphalan flufenamide

    go.drugbank.com/drugs/DB16627
    ApprovedWithdrawn

    It has since been withdrawn from the market in the wake of the phase 3 OCEAN trial which showed a decrease in overall survival in comparison to standard treatment with [pomalidomide] and [dexamethasone … [A230143,L32173] Melphalan flufenamide was granted FDA approval on 26 February 2021.[L32173].

  4. Drug

    Zopapogene imadenovec

    go.drugbank.com/drugs/DB24672
    ApprovedInvestigational

    [L54081] Zopapogene imadenovec is a non-replicating adenoviral vector–based immunotherapy that expresses a fusion antigen from selected regions of HPV-6/11 proteins to elicit an immune response in RRP. … Food and Drug Administration (FDA) for the treatment of adults with RRP, receiving full FDA approval on August 15, 2025.[L54081]

    Synonyms: DNA (recombinant replication-deficient Gorilla gorilla gorilla adenovirus strain GC4 vector PRGN-2012 human cytomegalovirus promoter plus human papillomavirus 6/11 E2, E4, E6, E7 protein 11 epitope-containing, Replication-deficient gorilla adenovirus vector (strain GC46) encoding human papillomavirus (HPV) type 6 and type 11 antigens comprising 11 epitopes derived from regions of the E2, E4, E6, and E7 proteins
  5. Drug

    Zucapsaicin

    go.drugbank.com/drugs/DB09120
    ApprovedWithdrawn

    Zucapsaicin was approved by the Health Canada in 2010 as topical cream marketed under the brand name Zuacta but currently not FDA-approved.

  6. Drug

    Moxifloxacin

    go.drugbank.com/drugs/DB00218
    ApprovedInvestigational

    Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.

    Products: MOXIFLOXACINA DOUBLE-E PHARMA
  7. Drug

    Casein

    go.drugbank.com/drugs/DB10516
    Approved

    Casein allergenic extract is used in allergenic testing.

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Afatinib

    go.drugbank.com/drugs/DB08916
    ApprovedInvestigational

    Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. … use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by an

  9. Drug

    Sotatercept

    go.drugbank.com/drugs/DB12118
    ApprovedInvestigational

    [A263481] Sotatercept was approved by the European Commission on August 26, 2024.[L51549] … Sotatercept is an activin signalling inhibitor.

  10. Drug

    Rifamycin

    go.drugbank.com/drugs/DB11753
    ApprovedInvestigationalWithdrawn

    All of the derivatives have slight different physicochemical properties when compared to the parent structure. … The parent compound of rifamycin was rifamycin B which was originally obtained as a main product in the presence of diethylbarburitic acid.